<DOC>
	<DOCNO>NCT00818662</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 2 dos Immune Globulin Intravenous ( IGIV ) , 10 % administer every 2 week intravenous ( IV ) infusion compare placebo participant mild moderate Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>A Phase 3 Study Evaluating Safety Effectiveness Immune Globulin Intravenous ( IGIV 10 % ) Treatment Mild-to-Moderate Alzheimer´s Disease</brief_title>
	<detailed_description>Study visit : Each participant test investigational site , qualify , treat intravenously ( vein ) every two week 70 week ( approximately 18 month ) . The first three infusion must do site , infusion well tolerate , subsequent infusion may do qualify healthcare provider home suitable location . Each participant must return site every 3 month evaluation cognition well blood test scan brain .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Main Written inform consent participant ( participant´s legally acceptable representative ) caregiver willing able participate duration study Diagnosis probable Alzheimer´s Disease ( AD ) Dementia mild moderate severity define minimental state examination ( MMSE ) 1626 inclusive time screen Neuroimaging ( compute tomography [ CT ] MRI ) perform symptom onset consistent AD diagnosis Ability comply test infusion regimen , include fluency English Spanish , adequate correct visual acuity hear ability On stable dos regulatory authority approve AD medication ( ) least 3 month prior screen . These medication must continue throughout study . If receive psychoactive medication ( e.g . antidepressant monoamine oxidase inhibitor ( MAOIs ) tricyclic , antipsychotic , anxiolytic , anticonvulsant , mood stabilizer , etc ) , must stable dos least 6 week prior screen Main Exclusion Criteria ( Reasons might appropriate participate ) : Any form dementia Medical issue might increase risk treatment IGIV , 10 % , : 1 . Significant problem blood pressure , heart disease , clot disorder , stroke recent heart attack 2 . Evidence current bleeding brain MRI 3 . Serious problem liver kidney 4 . Allergies blood product Medical issue might interfere evaluation treatment dementia might make dementia bad , : 1 . Diabetes 2 . Recent treatment chemotherapy immune suppression 3 . The recent use investigational drug , especially antibody therapy AD 4 . Severe headache psychiatric problem</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Alzheimer´s</keyword>
	<keyword>Dementia</keyword>
	<keyword>Dementia Alzheimer Type</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>Gammaglobulins</keyword>
	<keyword>Immune Globulin Intravenous ( IGIV )</keyword>
	<keyword>Intravenous Immune Globulin ( IVIG )</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Amyloid</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>